JP2023516717A - Chemical control injection device - Google Patents

Abstract

An embodiment of the present invention provides a blood glucose measuring unit configured to measure blood glucose of an infused subject at least sequentially multiple times; A first drug solution injection part configured to inject a drug solution into an injection target, and a second drug solution containing a component that controls an increase in blood sugar of the injection target and a component different from the first drug solution is injected into the injection target. and a second drug injector configured to. [Selection drawing] Fig. 1

Description

Embodiments of the present invention relate to controlled injection devices.

If the body's functions are not working properly, it may be necessary to inject a chemical solution from the outside. .

On the other hand, the drug injection device for injecting the drug solution into the injection target often needs to be used multiple times or for a long period of time, so that the injection target experiences inconvenience and pain.

Further, in some cases, the infusion subject may require infusion of different medical fluids, for example complementary medical fluids to be infused as blood glucose levels decrease or increase.

On the other hand, in order to increase the effect of injecting the drug solution to the patient, the drug injection device needs to control the precise injection of the drug solution into the patient's body. There is a limit to the precise injection of, for example, one or more sequential and precise injections of the drug solution.

Embodiments of the present invention provide a liquid controlled injection device that improves convenience and stability.

One embodiment of the present invention includes a blood glucose measuring unit configured to measure the blood glucose of an injection target at least sequentially a plurality of times; a first drug solution injection part configured to inject into a subject; and a second drug solution containing a component for controlling an increase in blood sugar of the injection target and a component different from the first drug solution to be injected into the target. and a second drug injection portion formed.

In this embodiment, the first chemical injection part and the second chemical injection part may be configured to selectively inject the first chemical solution or the second chemical solution into the injection target.

The present embodiment may further include a control unit configured to control driving of the first chemical injection unit and the second chemical injection unit according to blood glucose information measured by the blood glucose measurement unit.

In this embodiment, the first chemical injection unit or the second chemical injection unit includes a housing, and the blood glucose measurement unit is arranged in the housing of the first chemical injection unit or the second chemical injection unit. can include

The present embodiment may include a housing formed to include at least one of the blood glucose measuring part, the first drug injection part, and the second drug injection part.

In the present embodiment, the drug control injection device may be configured to communicate with a separate terminal to transmit one or more pieces of information.

In this embodiment, the drug solution control injection device may include a device attached to the outside of the user's body and having a wearable function.

Other aspects, features and advantages in addition to those mentioned above will become apparent from the following drawings, claims and detailed description of the invention.

The drug solution control injection device according to this embodiment can improve convenience and stability.

FIG. 2 illustrates an exemplary use of a controlled injection device for liquids according to an embodiment of the present invention; FIG. 2 is a schematic diagram for explaining the drug solution control injection device of FIG. 1; FIG. 4 is a schematic diagram for explaining a drug solution control injection device according to another embodiment of the present invention; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 6 is a view showing a modification of the first chemical injection part of FIG. 5; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 8 is a perspective view showing an example of a first chemical liquid injector of FIG. 7; FIG. 9 is a schematic plan view of the first chemical injection part of FIG. 8; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 11 is a perspective view showing an example of a first chemical liquid injector of FIG. 10; FIG. 12 is a schematic front view of the first chemical injection part of FIG. 11; FIG. 12 is a schematic plan view of the first chemical injection part of FIG. 11; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 10 is a schematic diagram for explaining a drug-solution control injection device according to still another embodiment of the present invention; FIG. 10 illustrates an alternative embodiment of a driver included in a drug control injection device according to yet another embodiment of the present invention; FIG. 10 illustrates an alternative embodiment of a driver included in a drug control injection device according to yet another embodiment of the present invention; FIG. 11 is a perspective view showing an alternative embodiment of a drive portion included in a drug control injection device according to still another embodiment of the present invention; FIG. 20 is a cross-sectional view taken along line XX-XX of FIG. 19; Fig. 10 is a perspective view of another alternative embodiment of a liquid controlled injection device according to yet another embodiment of the present invention;

Since the present invention can be modified in various ways and can have various embodiments, specific embodiments will be illustrated in the drawings and will be described in detail. The advantages and features of the present invention, as well as the manner in which they are achieved, will become apparent with reference to the embodiments described in detail below in conjunction with the drawings. This invention, however, is not limited to the embodiments disclosed below, and may be embodied in various forms.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. Description is omitted.

In the following embodiments, the terms first, second, etc. are used in a non-limiting sense to distinguish one component from another.

In the following embodiments, singular expressions include plural expressions unless the context clearly dictates a different meaning.

In the following embodiments, terms such as including or having mean that the feature or component recited in the specification is present, to the addition of one or more other features or components. The possibility is not excluded in advance.

In the drawings, the sizes of components may be exaggerated or reduced for convenience of explanation. For example, the size and thickness of each component shown in the drawings are arbitrarily shown for convenience of explanation, and the present invention is not necessarily limited to those shown.

In the following embodiments, the x-axis, y-axis and z-axis are not limited to the three axes on the Cartesian coordinate system, but can be interpreted in a broader sense including them. For example, the x-, y-, and z-axes may be orthogonal to each other, but may point in different non-orthogonal directions.

Where an embodiment can be implemented in other ways, the specific order of steps may be performed out of the order described. For example, two steps described in succession may be performed substantially simultaneously, or may be performed in the reverse order from that described.

FIG. 1 is a diagram exemplifying the use of a chemical liquid controlled injection device according to an embodiment of the present invention, and FIG. 2 is a schematic diagram for explaining the chemical liquid controlled injection device of FIG.

Referring to FIG. 1, it is shown that the liquid injection device 500 is placed outside the user's body part HB.

As an example, as shown in FIG. 1, an injection needle for injecting one or more drug solutions, a sensor for measuring blood sugar, etc. can be inserted through the body part HB.

If the user has diabetes or is having difficulty in controlling blood sugar due to his/her physical ability for other reasons, he or she can externally inject a drug solution to control the abnormal blood sugar increase or decrease.

Via the drug injection device 500 of the present embodiment, the user can inject different drug solutions to suppress abnormal increases or decreases in blood glucose.

Referring to FIG. 2 , the drug injection device 500 of the present embodiment may include a blood glucose measurement part 100 , a first drug injection part 200 and a second drug injection part 300 .

The blood glucose measuring unit 100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measuring unit 100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set time, e.g. monitoring).

The first drug injection unit 200 may be configured to inject into the user a first drug solution containing a component for controlling blood sugar reduction of the user by reflecting the blood sugar information measured by the blood sugar measurement unit 100 .

For example, the first liquid medicine injected to the user through the first liquid medicine injector 200 may contain insulin.

As an alternative embodiment, the first chemical injector 200 may include a reservoir (not shown) that stores the first chemical.

In addition, as an alternative embodiment, the first liquid medicine injector 200 may include a module for injecting the first liquid medicine to the user, for example, a needle module (not shown). can easily inject the first chemical liquid into the user's skin.

As an alternative embodiment, the first drug injection part 200 may include a driving part (not shown) that transfers the first drug solution in the reservoir to the needle module. For example, such drives may include actuators. The drive may also include a pump. A predetermined amount of the first liquid medicine may be injected by the user through driving of the driving unit.

As an alternative embodiment, the driving part included in the first chemical injection part or the second chemical injection part in the embodiments described later may also include an actuator, and as another example, it may include a pump.

The first drug solution injection unit 200 can use the blood sugar information from the blood sugar measurement unit 100 to inject the first drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 100 and the first drug injection unit 200 may include a communication unit NW for connecting to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 100 exceeds a set range via a control unit (not shown), the first chemical injection unit 200 can inject the first chemical, For example, the driving section can be controlled via a control section (not shown) to control the injection of the drug solution into the needle module.

Such a control unit (not shown) may be included in the blood glucose measurement unit 100 and may be included in the first drug injection unit 200 or the second drug injection unit 300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 100, and the user operates the control unit to control the injection of the first chemical injection unit 200 or the second chemical injection unit 300. You can also

As an alternative embodiment, the controller may sense interaction of injection of the first drug injector 200 or the second drug injector 300 and control each. For example, the controller can reduce or prevent the influence of interaction between the first chemical and the second chemical.

For example, after the injection of the first chemical solution, the control unit may limit the injection of the second chemical solution during the maximum effect generation time of the injection of the first chemical solution. , the injection of the second chemical solution can be reduced. Such maximum effect occurrence time may be a preset time. Further, as an alternative embodiment, the maximum effect occurrence time is a variable value, and the control unit calculates the maximum effect occurrence time by grasping the value measured by the blood glucose measurement unit 100 or the change in such value. can then be analyzed whether to block the injection of the second medical fluid or reduce the injection of the second medical fluid.

As another example, after the injection of the second liquid medicine, the control unit can limit the injection of the first liquid medicine during the maximum effect generation time due to the injection of the second liquid medicine. It can be blocked or the injection of the first chemical solution can be reduced. Such maximum effect occurrence time may be a preset time. Further, as an alternative embodiment, the maximum effect occurrence time is a variable value, and the control unit calculates the maximum effect occurrence time by grasping the value measured by the blood glucose measurement unit 100 or the change in such value. can then be analyzed whether to block the injection of the first medical fluid or reduce the injection of the first medical fluid.

As an alternative embodiment, the control unit can calculate the injection amount of each of the first medical solution and the second medical solution by taking into consideration the antagonistic action of the first medical solution and the second medical solution.

For example, the half-life and the time to complete elimination of the first chemical solution and the second chemical solution may be used, and such values may be preset values. Such time information can be used to calculate each injection dose.

The first chemical injection and the second chemical injection of the controller can be selectively applied to the embodiments described later.

On the other hand, in an embodiment described later, when a needle module for injecting the first chemical solution and a needle module for injecting the second chemical solution are provided, the respective needle modules are controlled to produce the first chemical solution and the second chemical solution. injection can be easily controlled individually.

Further, when the needle module for injecting the first chemical solution and the injection of the second chemical solution are formed in common, as a specific example, in the case of FIG. 15, the valve VL can be used for control. As an alternative embodiment, a first chemical injection restricting member (not shown) provided between the valve VL and the first chemical injection part 7200 or in the first chemical injection part 7200 can be further arranged. Therefore, when it is necessary to limit unnecessary mixing such as replacement injection of the first chemical liquid and the second chemical liquid, the restriction of the first chemical liquid can be easily controlled.

In addition, as an alternative embodiment, a second chemical injection restricting member (not shown) provided between the valve VL and the second chemical injection part 7300 or in the second chemical injection part 7300 can be further arranged. This makes it possible to easily control the restriction of the second chemical liquid when it is necessary to restrict unnecessary mixing such as replacement injection of the first chemical liquid and the second chemical liquid.

The second liquid medicine injector 300 may be configured to inject a second liquid medicine containing a component for controlling an increase in the user's blood sugar by reflecting the blood sugar information measured by the blood sugar measuring part 100 .

For example, the second drug solution injected to the user through the second drug injection part 300 may contain glucagon.

As an alternative embodiment, the second chemical injector 300 may include a reservoir (not shown) that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 300 may include a module for injecting the second liquid medicine to the user, for example, a needle module (not shown). can easily inject the second liquid medicine into the inside of the user's skin.

As an alternative embodiment, the second drug injection part 300 may include a driving part (not shown) that transfers the second drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the second liquid medicine through pumping of the pump.

The second drug solution injection unit 300 can use the blood sugar information from the blood sugar measurement unit 100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 100 and the second drug injection unit 300 may include a communication unit NW to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 100 is below a set range via a control unit (not shown), the second chemical injection unit 300 can inject the second chemical. For example, it can control the drive unit and control the injection of the drug solution into the needle module.

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

For example, when the blood glucose level exceeds the set range by looking at the value measured by the blood glucose measuring unit, the first chemical solution such as insulin is injected through the first chemical solution injection unit to reduce the blood sugar level and return it to the normal blood sugar range. can have.

As another example, when the blood sugar level is below the set range according to the value measured by the blood sugar measuring unit, a second liquid medicine such as glucagon is injected through the second liquid medicine injection part to increase the blood sugar level. It can have a normoglycemic range.

Such control can be implemented in various ways. part can be controlled.

As another example, the control unit receives blood sugar level information measured by the blood sugar measuring unit in real time according to a preset blood sugar setting range, and when the setting range is exceeded, It is possible to inject the first chemical solution, and if it is less than the set range, the second chemical solution can be injected through the second chemical injection part.

As a result, the user's convenience can be improved, the inaccuracy of the drug solution adjustment due to the user's inexperience in operation can be eliminated, and the injection of the first drug solution and the second drug solution can be precisely controlled, thereby improving the user's blood sugar. It can be controlled precisely.

FIG. 3 is a schematic diagram for explaining a chemical liquid control injection device according to another embodiment of the present invention.

Referring to FIG. 3 , the drug injection device 1500 of the present embodiment may include a blood glucose measurement part 1100 , a first drug injection part 1200 and a second drug injection part 1300 .

The blood glucose measurement unit 1100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measuring unit 1100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set time, e.g. monitoring).

The blood glucose measuring unit 1100 may be formed to be included in the first liquid medicine injection unit 1200 . For example, the blood glucose measuring unit 1100 may be partially or entirely disposed inside the housing (not shown) of the first drug injection unit 1200 .

The first drug injection unit 1200 may be configured to inject into the user a first drug solution that reflects the blood glucose information measured by the blood glucose measurement unit 1100 and includes a component that controls the decrease in blood glucose of the user.

For example, the first liquid medicine injected to the user through the first liquid medicine injector 1200 may contain insulin.

As an alternative embodiment, the first chemical injector 1200 may include a reservoir (not shown) that stores the first chemical.

In addition, as an alternative embodiment, the first liquid medicine injector 1200 may include a module, such as a needle module (not shown), for injecting the first liquid medicine to the user. can easily inject the first chemical liquid into the user's skin.

As an alternative embodiment, the first drug solution injector 1200 may include a driving part (not shown) that transfers the first drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the first medical solution through pumping of the pump.

The first drug solution injection unit 1200 can inject the first drug solution once, multiple times, or continuously as needed using the blood sugar information from the blood sugar measurement unit 1100 .

The first liquid medicine injection part 1200 may be integrally formed with the blood glucose measurement part 1100 . For example, at least one region of the blood glucose measuring unit 1100 may be disposed in one region of the first drug injection unit 1200, for example, the housing.

In addition, as an alternative embodiment, it may be formed on a region of the first drug injection part 1200, and for example, the blood glucose measurement part 1100 may be disposed on a substrate-shaped main body.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 1100 exceeds a set range through a control unit (not shown), the first chemical injection unit 1200 can inject the first chemical, For example, the driving section can be controlled via a control section (not shown) to control the injection of the drug solution into the needle module.

Such a control unit (not shown) may be included in the blood glucose measurement unit 1100 and may be included in the first drug injection unit 1200 or the second drug injection unit 1300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 1100, and the user operates the control unit to control the injection of the first chemical injection unit 1200 or the second chemical injection unit 1300. You can also

The second drug injection unit 1300 may be configured to inject a second drug solution containing a component for controlling an increase in blood sugar of the user by reflecting the blood sugar information measured by the blood sugar measurement unit 1100 .

For example, the second drug solution injected to the user through the second drug solution injector 1300 may contain glucagon.

As an alternative embodiment, the second chemical injector 1300 may include a reservoir (not shown) that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 1300 may include a module, for example, a needle module (not shown) for injecting the second liquid medicine to the user, and the needle module may be used to inject the second liquid medicine into the user. can easily inject the second liquid medicine into the inside of the user's skin.

As an alternative embodiment, the second drug solution injector 1300 may include a driving part (not shown) that transfers the second drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the second liquid medicine through pumping of the pump.

The second drug solution injection unit 1300 can use the blood sugar information from the blood sugar measurement unit 1100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 1100 and the second drug injection unit 1300 may include a communication unit NW to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 1100 is below a set range via a control unit (not shown), the second chemical injection unit 1300 can inject the second chemical. For example, it can control the drive unit and control the injection of the drug solution into the needle module.

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

Also, the blood glucose measuring part may be included in the first liquid medicine injection part, or may be formed so as to include at least one region. For example, at least one region of the blood glucose measuring unit may be disposed within the housing of the first liquid injector, and as an example, at least one region of the blood glucose measuring unit may be disposed in the substrate-shaped main body of the first liquid injector. can be placed.

Also, the blood glucose measurement unit may be integrated with the first chemical injection unit, which can enhance the convenience of handling and management of the blood glucose measurement unit and the first chemical injection unit.

In addition, although not shown, the blood glucose measurement unit may be included in the second drug injection unit or may be formed to include at least one region.

User convenience can be enhanced through the drug control injection device of the present embodiment, and the injection of the first drug solution and the second drug solution can be precisely controlled, thereby precisely controlling the blood sugar of the user.

FIG. 4 is a schematic diagram for explaining a chemical liquid control injection device according to still another embodiment of the present invention.

Referring to FIG. 4 , the drug injection device 2500 of the present embodiment may include a blood glucose measurement part 2100 , a first drug injection part 2200 , a second drug injection part 2300 and a housing 2510 .

The housing 2510 can have a unitary form, eg, a box shape.

As an alternative embodiment, the housing 2510 can have a configuration that includes a separate cover.

A part or all of the blood glucose measuring part 2100 , the first drug injection part 2200 and the second drug injection part 2300 may be covered with the housing 2510 .

For example, a cover (not shown) of the housing 2510 may cover one area or the entire area of the blood glucose measuring part 2100 , the first drug injection part 2200 and the second drug injection part 2300 .

The blood glucose measurement unit 2100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 2100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set period of time, such as a continuous glucose meter (CGM). monitoring).

The first liquid medicine injection unit 2200 may be configured to reflect the blood glucose information measured by the blood glucose measurement unit 2100 and inject the first liquid medicine including components for controlling the decrease in blood glucose of the user to the user.

For example, the first liquid medicine injected to the user through the first liquid medicine injector 2200 may contain insulin.

As an alternative embodiment, the first chemical injector 2200 may include a reservoir (not shown) that stores the first chemical.

In addition, as an alternative embodiment, the first liquid medicine injector 2200 may include a module, such as a needle module (not shown), for injecting the first liquid medicine to the user. can easily inject the first chemical liquid into the user's skin.

As an alternative embodiment, the first drug solution injector 2200 may include a driving part (not shown) that transfers the first drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the first medical solution through pumping of the pump.

The first drug solution injection unit 2200 can inject the first drug solution once, multiple times, or continuously as needed using the blood sugar information from the blood sugar measurement unit 2100 .

As an alternative embodiment, the blood glucose measurement unit 2100 and the first drug injection unit 2200 may include a communication unit NW for connecting to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 2100 exceeds a set range through a control unit (not shown), the first chemical injection unit 2200 can inject the first chemical, For example, the driving section can be controlled via a control section (not shown) to control the injection of the drug solution into the needle module.

Such a control unit (not shown) may be included in the blood glucose measuring unit 2100 and may be included in the first drug injection unit 2200 or the second drug injection unit 2300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 2100, and the user operates the control unit to control the injection of the first chemical injection unit 2200 or the second chemical injection unit 2300. You can also

The second liquid medicine injection part 2300 may be configured to inject a second liquid medicine containing a component for controlling an increase in blood sugar of the user by reflecting the blood sugar information measured by the blood sugar measuring part 2100 .

For example, the second drug solution injected to the user through the second drug solution injector 2300 may contain glucagon.

As an alternative embodiment, the second chemical injector 2300 may include a reservoir (not shown) that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 2300 may include a module, such as a needle module (not shown), for injecting the second liquid medicine to the user. can easily inject the second liquid medicine into the inside of the user's skin.

As an alternative embodiment, the second drug solution injector 2300 may include a driving part (not shown) that transfers the second drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the second liquid medicine through pumping of the pump.

The second drug solution injection unit 2300 can inject the second drug solution once, multiple times, or continuously as needed using the blood sugar information from the blood sugar measurement unit 2100 .

As an alternative embodiment, the blood glucose measurement unit 2100 and the second drug injection unit 2300 may include a communication unit NW to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 2100 is below a set range via a control unit (not shown), the second chemical injection unit 2300 can inject the second chemical. For example, it can control the drive unit and control the injection of the drug solution into the needle module.

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

Also, the housing may include all or at least one of the blood glucose measuring part, the first drug injection part, and the second drug injection part. For example, a cover included in the housing can cover the blood glucose measurement part, the first drug injection part, or the second drug injection part.

Further, the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit may be integrated through one housing, and the blood glucose measurement unit, the first chemical injection unit and the second chemical injection unit may be integrated. The convenience of handling and management can be enhanced.

User convenience can be enhanced through the drug control injection device of the present embodiment, and the injection of the first drug solution and the second drug solution can be precisely controlled, thereby precisely controlling the blood sugar of the user.

FIG. 5 is a schematic diagram for explaining a chemical liquid control injection device according to still another embodiment of the present invention.

Referring to FIG. 5 , the drug injection device 3500 of the present embodiment may include a blood glucose measurement part 3100 , a first drug injection part 3200 and a second drug injection part 3300 .

Also, although not shown, as an alternative embodiment, the drug injection device 3500 of the present embodiment may further include a housing (not shown) as described in the previous embodiments.

The blood glucose measurement unit 3100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 3100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set time, e.g., a continuous glucose meter (CGM). monitoring).

The first liquid medicine injection unit 3200 may be configured to reflect the blood sugar information measured by the blood sugar measurement unit 3100 and inject the first liquid medicine including components for controlling the decrease of the user's blood sugar to the user.

For example, the first liquid medicine injected to the user through the first liquid medicine injector 3200 may contain insulin.

As an alternative embodiment, the first chemical injector 3200 may include a reservoir 3210 that stores the first chemical.

The reservoir 3210 includes one or more outer portions 3211 and can accommodate the first chemical solution in an inner space formed inside the outer portions 3211 .

The reservoir 3210 may include a storage space in the form of a tank for storing the drug solution. The storage part 3210 may include a waterproof material capable of containing a drug solution, such as a plastic-based material, or may be made of various other materials. For example, it may contain glass, metal, or silicon materials.

In addition, although not shown, the reservoir 3210 may include one or more motion members (not shown) in a space in which the drug solution is stored inside the outer portion 3211. Such motion members may include: The first medical solution can be effectively moved, and more specifically, the medical solution stored in the reservoir 3210 can be easily transferred to the needle module 3230, which will be described later.

Also, as an alternative embodiment, the first liquid medicine injector 3200 may include a module, eg, a needle module 3230, for injecting the first liquid medicine to the user.

Needle module 3230 can include at least one needle portion ND. The needle part ND has a hollow shape, and the first drug solution of the storage part 3210 can be injected into the injection target through the internal space.

A connection TN can be placed between the needle module 3230 and the reservoir 3210 . The connection part TN may include a transmission area such that at least the first drug solution in the storage part 3210 is transmitted to the needle module 3230, and may include a hollow tube shape, for example.

The connection part TN can be formed in various forms, and can include, for example, the form of a flexible tube.

Through such a needle module 3230, the first medical solution can be easily injected into the user's skin.

As an alternative embodiment, the first drug solution injector 3200 may include a driving part 3220 that transfers the first drug solution from the reservoir to the needle module.

The driving unit 3220 transfers the first liquid medicine stored in the storage part 3210 to the needle module 3230 so that the first liquid medicine can be easily injected from the needle module 3230 into the injection target, for example, the human skin. can be made

As an alternative embodiment, the driving part 3220 may include a pump, and a certain amount of the first drug solution stored in the storage part 3210 may be transferred toward the needle module 3230 through pumping of the pump.

Although not shown, the driving unit 3220 may be connected to a power supply unit (not shown), and such a power supply may have various forms such as an external power supply, a disposable battery, or a rechargeable battery. can be done.

In addition, as an alternative embodiment, the driving unit 3220 is electrically connected to a controller (not shown), and the driving unit 3220 can control injection of the first chemical solution through the control of the controller.

The driving unit 3220 may use any kind of pump having a chemical liquid suction force and a chemical liquid discharge force by electricity. All kinds of pumps can be used, for example mechanical displacement micropumps or electromagnetic kinematic micropumps. A mechanical displacement micropump is a pump that utilizes solid or fluid motion, such as gears or diagrams, to create a pressure differential to induce fluid flow; There are pumps (fluid displacement pumps), rotary pumps, and the like. An electro-magnetokinetic micropump is a pump that directly utilizes energy in the form of electric or magnetic to move a fluid, and includes electrohydrodynamic pumps (EHD), electroosmotic pumps, There are a magneto hydrodynamic pump, an electro wetting pump, and the like.

The driving part 3220 of the present embodiment may be connected to the storage part 3210 so that the first drug solution stored in the storage part 3210 can be easily transferred to the needle module 3230 through the connection part TN.

The first drug solution injection unit 3200 can inject the first drug solution once, multiple times, or continuously as needed using the blood sugar information from the blood sugar measurement unit 3100 .

As an alternative embodiment, the blood glucose measurement unit 3100 and the first liquid medicine injection unit 3200 may include a communication unit NW for connecting to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 3100 exceeds a set range through a control unit (not shown), the first chemical injection unit 3200 can inject the first chemical, For example, the driver 3220 can be controlled via a controller (not shown) to control the injection of the drug solution by the needle module 3230 .

Such a control unit (not shown) may be included in the blood glucose measurement unit 3100 and may be included in the first drug injection unit 3200 or the second drug injection unit 3300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 3100, and the user operates the control unit to control the injection of the first chemical injection unit 3200 or the second chemical injection unit 3300. You can also

FIG. 6 is a view showing a modification of the first chemical injection part of FIG. 5. FIG.

Referring to FIG. 6, the first drug injection part 3200' may include a storage part 3210', a driving part 3220', and a needle module 3230'.

A first connection part TN1 may be disposed between the storage part 3210′ and the driving part 3220′, and the first connection part TN1 allows at least the first chemical liquid in the storage part 3210′ to flow toward the driving part 3220′. A transmission region can be included to be transmitted, for example, it can include a hollow tube configuration. The first connection part TN1 may be formed in various forms, and may include, for example, a flexible tube form.

A second connecting part TN2 may be disposed between the driving part 3220′ and the needle module 3230′, and the second connecting part TN2 allows at least the first drug solution to flow from the driving part 3220′ to the needle module 3230′. A transmission region can be included to be transmitted, for example, it can include a hollow tube configuration. The second connection part TN2 can be formed in various forms, and can include, for example, a flexible tube form.

The second drug injection unit 3300 may be configured to reflect the blood sugar information measured by the blood sugar measurement unit 3100 and inject a second drug solution containing components for controlling an increase in blood sugar of the user.

For example, the second drug solution injected to the user through the second drug solution injector 3300 may contain glucagon.

As an alternative embodiment, the second chemical injector 3300 may include a reservoir (not shown) that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 3300 may include a module, such as a needle module (not shown), for injecting the second liquid medicine to the user. can easily inject the second liquid medicine into the inside of the user's skin.

As an alternative embodiment, the second drug solution injector 3300 may include a driving part (not shown) that transfers the second drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the second liquid medicine through pumping of the pump.

The second drug solution injection unit 3300 can use the blood sugar information from the blood sugar measurement unit 3100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measuring unit 3100 and the second drug injection unit 3300 may include a communication unit NW to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 3100 is below a set range via a control unit (not shown), the second chemical injection unit 3300 can inject the second chemical. For example, it can control the drive unit and control the injection of the drug solution into the needle module.

Although not shown, the second drug injection part 3300 may include all or part of the same configuration as the driving part, storage part, and needle module included in the first drug injection part 3200 . Also, the second chemical injection part 3300 may include the same configuration or a part of the modified example of FIG.

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

In addition, the first chemical injection part or the second chemical injection part includes a storage part for storing the chemical solution, a needle module configured to inject the chemical solution into the injection target, and a driving part for driving the movement of the chemical solution. can contain. With such a configuration, smooth injection of the first chemical solution or the second chemical solution can be easily implemented.

As a result, the user's convenience can be enhanced through the liquid medicine control injection device of the present embodiment, and the injection of the first liquid medicine and the second liquid medicine can be precisely controlled, thereby precisely controlling the blood sugar of the user. can be done.

FIG. 7 is a schematic diagram for explaining a drug solution control injection device according to still another embodiment of the present invention, and FIG. 8 is a perspective view showing an example of the first drug solution injection part of FIG. 9 is a schematic plan view of the first chemical injection part of FIG. 8;

7 to 9, the drug injection device 4500 of the present embodiment may include a blood glucose measurement part 4100, a first drug injection part 4200, and a second drug injection part 4300. FIG.

Also, although not shown, as an alternative embodiment, the drug injection device 4500 of the present embodiment may further include a housing (not shown) as described in the previous embodiments.

The blood glucose measurement unit 4100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 4100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set period of time, such as a continuous glucose meter (CGM). monitoring).

The first drug injection part 4200 may include a cover 4201 , and the cover 4201 may be formed to cover the storage part 4210 , the driving part 4220 and the needle module 4230 .

For convenience of explanation, FIG. 9 shows the state in which the cover 4201 of FIG. 8 is removed.

The first chemical injection part 4200 may include a base 4202 , and the base 4202 may be formed to face the cover 4201 .

As an alternative embodiment, the cover 4201 and the base 4202 may be connected to each other to form a housing for the first drug injection part 4200 .

As an alternative embodiment, the cover 4201 can include apertures, and a button 4235 can be positioned to correspond to such aperture, said button 4235 can correspond to the needle module 4230 .

For example, a button 4235 can be located on the needle module 4230, and the button 4235 can be configured to be pressurized or rotated by a user. Movement relative to needle module 4230 is possible through button 4235 .

The first drug injection unit 4200 may be configured to reflect the blood sugar information measured by the blood sugar measurement unit 4100 and inject the first drug solution containing a component for controlling the reduction of blood sugar of the user to the user.

For example, the first liquid medicine injected to the user through the first liquid medicine injector 4200 may contain insulin.

As an alternative embodiment, the first chemical injector 4200 may include a reservoir 4210 that stores the first chemical.

The reservoir 4210 includes one or more outer portions 4211 and can accommodate the first chemical solution in an inner space formed inside the outer portions 4211 .

The reservoir 4210 may include a storage space in the form of a tank for storing the drug solution. The storage part 4210 may include a waterproof material capable of containing a drug solution, such as a plastic-based material, or may be made of various other materials. For example, it may contain glass, metal, or silicon materials.

In addition, although not shown, the reservoir 4210 may include one or more motion members (not shown) in a space in which the drug solution is stored inside the outer portion 4211. Such motion members may include: The first medical solution can be effectively moved, and more specifically, the medical solution stored in the reservoir 4210 can be easily transferred to the needle module 4230, which will be described later.

In addition, although not shown, the reservoir 4210 includes a filling passage (not shown), and can be replenished with a chemical solution through the filling passage.

Also, as an alternative embodiment, the first liquid medicine injector 4200 may include a module, eg, a needle module 4230, for injecting the first liquid medicine to the user.

Needle module 4230 can include at least one needle portion ND. The needle part ND has a hollow shape, and the first drug solution of the storage part 4210 can be injected into the injection target through the internal space.

A connection TN can be placed between the needle module 4230 and the reservoir 4210 . The connection part TN may include a transmission area such that at least the first drug solution in the reservoir 4210 is transmitted to the needle module 4230, and may include a hollow tube shape, for example.

The connection part TN can be formed in various forms, and can include, for example, the form of a flexible tube.

Through such a needle module 4230, the first medical solution can be easily injected into the user's skin.

As an alternative embodiment, the first drug solution injector 4200 may include a driving part 4220 that transfers the first drug solution from the reservoir to the needle module.

The driving unit 4220 transfers the first liquid medicine stored in the storage part 4210 to the needle module 4230 so that the first liquid medicine can be easily injected from the needle module 4230 into the injection target, for example, the human skin. can be made

As an alternative embodiment, the driving part 4220 may include a pump, and a certain amount of the first drug solution stored in the storage part 4210 may be transferred toward the needle module 4230 through pumping of the pump.

The driving unit 4220 may be connected to a power unit 4250, and the power unit 4250 may include a battery, and may have various forms such as a disposable battery or a rechargeable battery.

In addition, as an alternative embodiment, the driving unit 4220 may be electrically connected to a controller (not shown), and the driving unit 4220 may control injection of the first chemical through control of the controller.

The driving unit 4220 may use any kind of pump having a chemical liquid suction force and a chemical liquid discharge force by electricity. All kinds of pumps can be used, for example mechanical displacement micropumps or electromagnetic movement micropumps. Mechanical displacement micropumps are pumps that use solid or fluid motion, such as gears or diagrams, to create pressure differentials to induce fluid flow, and include diaphragm displacement pumps and fluid displacement pumps. (Fluid displacement pump), rotary pump, and the like. An electro-magnetokinetic micropump is a pump that directly utilizes energy in the form of electric or magnetic to move a fluid, and includes electrohydrodynamic pumps (EHD), electroosmotic pumps, There are a magneto hydrodynamic pump, an electro wetting pump, and the like.

The driving part 4220 of the present embodiment is connected to the storage part 4210 so that the first drug solution stored in the storage part 4210 can be easily transferred to the needle module 4230 through the connection part TN.

The first drug solution injection unit 4200 can use the blood sugar information from the blood sugar measurement unit 4100 to inject the first drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 4100 and the first liquid medicine injection unit 4200 may include a communication unit NW for connecting to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 4100 exceeds a set range through a control unit (not shown), the first chemical injection unit 4200 can inject the first chemical, For example, the driver 4220 can be controlled via a controller (not shown) to control the injection of the drug solution by the needle module 4230 .

Such a control unit (not shown) may be included in the blood glucose measurement unit 4100 and may be included in the first drug injection unit 4200 or the second drug injection unit 4300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 4100, and the user operates the control unit to control the injection of the first chemical injection unit 4200 or the second chemical injection unit 4300. You can also

The second drug injection unit 4300 may be configured to inject a second drug solution containing a component for controlling an increase in blood sugar of the user by reflecting the blood sugar information measured by the blood sugar measurement unit 4100 .

For example, the second drug solution injected to the user through the second drug solution injector 4300 may contain glucagon.

As an alternative embodiment, the second chemical injector 4300 may include a reservoir (not shown) that stores the second chemical.

In addition, as an alternative embodiment, the second medical liquid injector 4300 may include a module, such as a needle module (not shown), for injecting the second medical liquid to the user. can easily inject the second liquid medicine into the inside of the user's skin.

As an alternative embodiment, the second drug solution injector 4300 may include a driving part (not shown) that transfers the second drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the second liquid medicine through pumping of the pump.

The second drug solution injection unit 4300 can use the blood sugar information from the blood sugar measurement unit 4100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 4100 and the second drug injection unit 4300 may include a communication unit NW to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 4100 is below a set range via a control unit (not shown), the second chemical injection unit 4300 can inject the second chemical. For example, it can control the drive unit and control the injection of the drug solution into the needle module.

Although not shown, the second drug injection unit 4300 may include all or part of the same configuration as the driving unit, storage unit, and needle module included in the first drug injection unit 4200 .

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

In addition, the first chemical injection part or the second chemical injection part includes a storage part for storing the chemical solution, a needle module configured to inject the chemical solution into the injection target, and a driving part for driving the movement of the chemical solution. can contain. With such a configuration, smooth injection of the first chemical solution or the second chemical solution can be easily implemented. In addition, the energy for driving the driving section can be easily supplied to the driving section through the power supply section, so that the operation of the liquid injection device can be smoothly maintained.

As a result, the user's convenience can be enhanced through the liquid medicine control injection device of the present embodiment, and the injection of the first liquid medicine and the second liquid medicine can be precisely controlled, thereby precisely controlling the blood sugar of the user. can be done.

FIG. 10 is a schematic diagram for explaining a drug solution control injection device according to still another embodiment of the present invention, and FIG. 11 is a perspective view showing an example of the first drug solution injection part of FIG. 12 is a schematic front view of the first chemical injection part of FIG. 11, and FIG. 13 is a schematic plan view of the first chemical injection part of FIG.

10 to 13, the drug injection device 5500 of the present embodiment can include a blood glucose measurement part 5100, a first drug injection part 5200, and a second drug injection part 5300. FIG.

Also, although not shown, as an alternative embodiment, the drug injection device 5500 of the present embodiment may further include a housing (not shown) as described in the previous embodiments.

The blood glucose measurement unit 5100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 5100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set time, e.g., a continuous glucose meter (CGM). monitoring).

The blood glucose measuring unit 5100 may be formed to be included in the first liquid medicine injection unit 5200, as shown in FIG. For example, the blood glucose measuring unit 5100 may be formed to be covered with a cover 5201 inside the housing of the first drug injection unit 5200 .

The first drug injection part 5200 may include a cover 5201 , and the cover 5201 may be formed to cover the storage part 5210 , the driving part 5220 and the needle module 5230 .

For convenience of explanation, FIG. 13 shows a state in which the cover 5201 of FIG. 11 is removed.

The first chemical injection part 5200 may include a base 5202 , and the base 5202 may be formed to face the cover 5201 .

As an alternative embodiment, the cover 5201 and the base 5202 may be connected to each other to form a housing for the first drug injection part 5200 .

As an alternative embodiment, the cover 5201 can include apertures and a button 5235 can be positioned to correspond to such aperture, said button 5235 can correspond to the needle module 5230 .

For example, a button 5235 can be positioned on the needle module 5230, and the button 5235 can be configured to be pressurized or rotated by a user. Movement relative to needle module 5230 is possible through button 5235 .

The first liquid medicine injection unit 5200 may be configured to reflect the blood sugar information measured by the blood sugar measurement unit 5100 and inject the first liquid medicine including components for controlling the decrease of the user's blood sugar to the user.

For example, the first drug solution injected to the user through the first drug solution injector 5200 may contain insulin.

As an alternative embodiment, the first chemical injector 5200 may include a reservoir 5210 that stores the first chemical.

The storage part 5210 includes one or more outer parts 5211 and can contain the first chemical solution in an inner space formed inside the outer parts 5211 .

The reservoir 5210 may include a storage space in the form of a tank for storing the drug solution. The storage part 5210 may include a waterproof material capable of containing a drug solution, such as a plastic-based material, or may be made of various other materials. For example, it may contain glass, metal, or silicon materials.

In addition, although not shown, the storage part 5210 may include one or more movement members (not shown) in a space in which the drug solution is stored inside the outer part 5211. Such movement members may include: The first medical solution can be effectively moved, and more specifically, the medical solution stored in the reservoir 5210 can be easily transferred to the needle module 5230, which will be described later.

In addition, although not shown, the reservoir 5210 includes a filling passage (not shown) through which the drug solution can be replenished.

Also, as an alternative embodiment, the first liquid medicine injector 5200 may include a module, eg, a needle module 5230, for injecting the first liquid medicine to the user.

Needle module 5230 can include at least one needle portion ND. The needle part ND has a hollow shape, and the first drug solution of the storage part 5210 can be injected into the injection target through the internal space.

A connection TN can be placed between the needle module 5230 and the reservoir 5210 . The connection part TN may include a transmission area such that at least the first drug solution in the reservoir 5210 is transmitted to the needle module 5230, and may include a hollow tube shape, for example.

The connection part TN can be formed in various forms, and can include, for example, the form of a flexible tube.

Through such a needle module 5230, the first medical solution can be easily injected into the user's skin.

As an alternative embodiment, the first drug solution injector 5200 may include a driving part 5220 that transfers the first drug solution from the reservoir to the needle module.

The driving unit 5220 transfers the first liquid medicine stored in the storage part 5210 to the needle module 5230 so that the first liquid medicine can be easily injected from the needle module 5230 into the injection target, for example, the human skin. can be made

As an alternative embodiment, the driving unit 5220 may include a pump, and the first drug solution stored in the storage unit 5210 may be transmitted toward the needle module 5230 by a certain amount through pumping of the pump.

The driving unit 5220 may be connected to a power unit 5250, and the power unit 5250 may include a battery, and may have various forms such as a disposable battery or a rechargeable battery.

In addition, as an alternative embodiment, the driving unit 5220 may be electrically connected to a controller (not shown), and the driving unit 5220 may control injection of the first chemical through control of the controller.

The driving unit 5220 may use any kind of pump having a chemical liquid suction force and a chemical liquid discharge force by electricity. All kinds of pumps can be used, for example mechanical displacement micropumps or electromagnetic movement micropumps. Mechanical displacement micropumps are pumps that use solid or fluid motion, such as gears or diagrams, to create pressure differentials to induce fluid flow, and include diaphragm displacement pumps and fluid displacement pumps. (Fluid displacement pump), rotary pump, and the like. An electro-magnetokinetic micropump is a pump that directly utilizes energy in the form of electric or magnetic to move a fluid, and includes electrohydrodynamic pumps (EHD), electroosmotic pumps, There are a magneto hydrodynamic pump, an electro wetting pump, and the like.

The driving part 5220 of the present embodiment is connected to the storage part 5210 so that the first drug solution stored in the storage part 5210 can be easily transferred to the needle module 5230 through the connection part TN.

As an alternative embodiment, a drive connection 5240 can be positioned between drive 5220 and reservoir 5210 .

The driving connection part 5240 receives driving force from the driving part 5220 and can transmit the driving force to a motion member (not shown) disposed inside the storage part 5210 . A moving member (not shown) inside the reservoir 5210 can be precisely controlled via the drive connection 5240, so that the first drug solution in the reservoir 5210 is finely controlled and supplied by the needle module 5230. be able to.

For example, drive connection 5240 can include one or more gear modules.

The first drug solution injection unit 5200 can use the blood sugar information from the blood sugar measurement unit 5100 to inject the first drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 5100 exceeds a set range through a control unit (not shown), the first chemical injection unit 5200 can inject the first chemical, For example, the driver 5220 can be controlled via a controller (not shown) to control injection of the drug solution by the needle module 5230 .

Such a control unit (not shown) may be included in the blood glucose measurement unit 5100 and may be included in the first drug injection unit 5200 or the second drug injection unit 5300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 5100, and the user operates the control unit to control the injection of the first chemical injection unit 5200 or the second chemical injection unit 5300. You can also

The second drug injection unit 5300 may be configured to inject a second drug solution containing a component for controlling an increase in blood sugar of the user by reflecting the blood sugar information measured by the blood sugar measurement unit 5100 .

For example, the second drug solution injected to the user through the second drug solution injector 5300 may contain glucagon.

As an alternative embodiment, the second chemical injector 5300 may include a reservoir (not shown) that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 5300 may include a module, such as a needle module (not shown), for injecting the second liquid medicine to the user. can easily inject the second liquid medicine into the inside of the user's skin.

As an alternative embodiment, the second drug solution injector 5300 may include a driving part (not shown) that transfers the second drug solution in the reservoir to the needle module. For example, such a driving unit may include a pump, and may cause the user to inject a predetermined amount of the second liquid medicine through pumping of the pump.

The second drug solution injection unit 5300 can use the blood sugar information from the blood sugar measurement unit 5100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 5100 and the second drug injection unit 5300 may include a communication unit NW to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 5100 is below a set range via a control unit (not shown), the second chemical injection unit 5300 can inject the second chemical. For example, it can control the drive unit and control the injection of the drug solution into the needle module.

Although not shown, the second drug injection unit 5300 may include all or part of the same configuration as the driving unit, storage unit, and needle module included in the first drug injection unit 5200 .

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

In addition, the first chemical injection part or the second chemical injection part includes a storage part for storing the chemical solution, a needle module configured to inject the chemical solution into the injection target, and a driving part for driving the movement of the chemical solution. can contain. With such a configuration, smooth injection of the first chemical solution or the second chemical solution can be easily implemented. In addition, the energy for driving the driving section can be easily supplied to the driving section through the power supply section, so that the operation of the liquid injection device can be smoothly maintained.

Also, the blood glucose measuring part may be included in the first liquid medicine injection part, or may be formed so as to include at least one region. As a result, the convenience of handling and management of the blood glucose measuring section and the first liquid medicine injection section can be enhanced.

In addition, although not shown, the blood glucose measurement unit may be included in the second drug injection unit or may be formed to include at least one region.

An alternative embodiment may include a drive connection coupled to the drive through which the motion inside the reservoir can be precisely controlled. As a result, minute supply amounts of the first chemical liquid and the second chemical liquid can be precisely controlled.

As a result, the user's convenience can be enhanced through the liquid medicine control injection device of the present embodiment, and the injection of the first liquid medicine and the second liquid medicine can be precisely controlled, thereby precisely controlling the blood sugar of the user. can be done.

FIG. 14 is a schematic diagram for explaining a chemical liquid controlled injection device according to still another embodiment of the present invention.

Referring to FIG. 14 , the drug injection device 6500 of the present embodiment may include a blood glucose measurement part 6100 , a first drug injection part 6200 , a second drug injection part 6300 and a housing 6510 .

The housing 6510 can have a unitary form, eg, a box shape.

As an alternative embodiment, the housing 6510 can have a form including a separate base and cover.

A part or the entire area of the blood glucose measuring part 6100 , the first drug injection part 6200 and the second drug injection part 6300 may be covered with the housing 6510 .

For example, a cover (not shown) of the housing 6510 may cover one area or the entire area of the blood glucose measuring part 6100, the first drug injection part 6200, and the second drug injection part 6300. FIG.

The blood glucose measurement unit 6100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 6100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set period of time, such as a continuous glucose meter (CGM). monitoring).

The first drug injection part 6200 may include a first storage part 6210 , a first driving part 6220 and a first needle module 6230 .

The first drug injection unit 6200 may be configured to reflect the blood sugar information measured by the blood sugar measurement unit 6100 and inject the first drug solution containing components for controlling the decrease in blood sugar of the user to the user.

For example, the first liquid medicine injected to the user through the first liquid medicine injector 6200 may contain insulin.

As an alternative embodiment, the first chemical injector 6200 may include a first reservoir 6210 that stores the first chemical.

Since the first storage unit 6210 can selectively apply any one of the storage units described in the above embodiments, a detailed description thereof will be omitted.

Also, as an alternative embodiment, the first liquid medicine injector 6200 may include a module, eg, a first needle module 6230, for injecting the first liquid medicine to the user.

The first needle module 6230 can include at least one needle portion ND. The needle part ND has a hollow shape, and the first drug solution of the first storage part 6210 can be injected into the injection target through the internal space.

Since the first needle module 6230 can selectively apply any one of the needle modules described in the above embodiments, a detailed description thereof will be omitted.

As an alternative embodiment, the first drug solution injector 6200 may include a first driving part 6220 that transfers the first drug solution from the reservoir to the needle module.

The first driving unit 6220 may be connected to a power supply (not shown).

Since the first driving unit 6220 can selectively apply any one of the driving units described in the above embodiments, a detailed description thereof will be omitted.

The first drug solution injection unit 6200 can use the blood sugar information from the blood sugar measurement unit 6100 to inject the first drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 6100 exceeds a set range via a control unit (not shown), the first chemical injection unit 6200 can inject the first chemical, For example, the first driver 6220 may be controlled through a controller (not shown) to control the injection of the drug solution by the first needle module 6230 .

Such a control unit (not shown) may be included in the blood glucose measurement unit 6100 and may be included in the first drug injection unit 6200 or the second drug injection unit 6300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 6100, and the user operates the control unit to control the injection of the first chemical injection unit 6200 or the second chemical injection unit 6300. You can also

The second drug injection part 6300 may include a second storage part 6310 , a second driving part 6320 and a second needle module 6330 .

The blood sugar information measured by the blood sugar measuring unit 6100 may be reflected to inject a second liquid medicine containing a component controlling an increase in the user's blood sugar to the user.

For example, the second drug solution injected to the user through the second drug solution injector 6300 may contain glucagon.

The second chemical injection part 6300 may include a second storage part 6310 that stores the second chemical.

In addition, as an alternative embodiment, the second medical fluid injection part 6300 may include a module for injecting the second medical fluid to the user, for example, a second needle module 6330, through which the second medical fluid is injected. The two drug solutions can be easily injected inside the user's skin.

As an alternative embodiment, the second drug solution injector 6300 may include a second driving part 6320 that transfers the second drug solution of the second reservoir 6310 to the second needle module 6330 .

The second drug solution injection unit 6300 can use the blood sugar information from the blood sugar measurement unit 6100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 6100 and the second drug injection unit 6300 may include a communication unit to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 6100 is below a set range via a control unit (not shown), the second chemical injection unit 6300 can inject the second chemical. For example, the second driving unit 6320 can be controlled to control the injection of the drug solution into the needle module.

Although not shown, the second drug injection part 6300 may include all or part of the same configuration as the driving part, storage part, and needle module included in the first drug injection part 6200 .

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

In addition, the first chemical injection part or the second chemical injection part includes a storage part for storing the chemical solution, a needle module configured to inject the chemical solution into the injection target, and a driving part for driving the movement of the chemical solution. can contain. With such a configuration, smooth injection of the first chemical solution or the second chemical solution can be easily implemented. In addition, the energy for driving the driving section can be easily supplied to the driving section through the power supply section, so that the operation of the liquid injection device can be smoothly maintained.

Also, the blood glucose measuring part, the first drug injection part, and the second drug injection part may be included in the housing, and for example, at least one region thereof may be covered by a cover of the housing. Also, as a specific example, it can have an integrated form. This makes it possible to enhance the convenience of handling and management of the liquid medicine control injection device including the blood glucose measuring section, the first liquid injection section, and the second liquid injection section.

As a result, the user's convenience can be enhanced through the liquid medicine control injection device of the present embodiment, and the injection of the first liquid medicine and the second liquid medicine can be precisely controlled, thereby precisely controlling the blood sugar of the user. can be done.

FIG. 15 is a schematic diagram for explaining a chemical control injection device according to still another embodiment of the present invention.

The housing 7510 can have a unitary form, eg, a box shape.

As an alternative embodiment, the housing 7510 can have a form that includes a separate base and cover.

A part or all of the blood glucose measuring part 7100 , the first drug injection part 7200 and the second drug injection part 7300 may be covered with the housing 7510 .

For example, a cover (not shown) of the housing 7510 may cover one area or the entire area of the blood glucose measuring part 7100 , the first drug injection part 7200 and the second drug injection part 7300 .

The blood glucose measurement unit 7100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 7100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set period of time, e.g. monitoring).

The first drug injection part 7200 may include a first storage part 7210 , a first driving part 7220 and a common needle module 7530 .

The first liquid medicine injection unit 7200 may be configured to inject a first liquid medicine including a component for controlling blood glucose reduction of the user by reflecting blood glucose information measured by the blood glucose measurement unit 7100 .

For example, the first drug solution injected to the user through the first drug solution injector 7200 may contain insulin.

As an alternative embodiment, the first chemical injector 7200 may include a first reservoir 7210 that stores the first chemical.

Since the first storage unit 7210 can selectively apply any one of the storage units described in the above embodiments, a detailed description thereof will be omitted.

Also, as an alternative embodiment, the first medical fluid injector 7200 may include a module, eg, a common needle module 7530, for injecting the first medical fluid to the user.

Common needle module 7530 can include at least one needle portion ND. The needle part ND has a hollow shape, and the first drug solution of the first storage part 7210 can be injected into the injection target through the internal space.

As an alternative embodiment, the first drug solution injector 7200 may include a first driving part 7220 that transfers the first drug solution from the reservoir to the needle module.

The first driver 7220 may be connected to a power supply (not shown).

Since the *364 first driving unit 7220 can selectively apply any one of the driving units described in the above embodiments, a detailed description thereof will be omitted.

The first drug solution injection unit 7200 can use the blood sugar information from the blood sugar measurement unit 7100 to inject the first drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 7100 exceeds a set range through a control unit (not shown), the first chemical injection unit 7200 can inject the first chemical, For example, the first driving unit 7220 may be controlled through a control unit (not shown) to control injection of the liquid by the common needle module 7530 .

Such a control unit (not shown) may be included in the blood glucose measurement unit 7100 and may be included in the first drug injection unit 7200 or the second drug injection unit 7300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 7100, and the user operates the control unit to control the injection of the first chemical injection unit 7200 or the second chemical injection unit 7300. You can also

The second drug injection part 7300 may include a second storage part 7310 , a second driving part 7320 and a common needle module 7530 .

The blood sugar information measured by the blood sugar measuring unit 7100 may be reflected to inject a second liquid medicine containing a component for controlling an increase in blood sugar of the user to the user.

For example, the second drug solution injected to the user through the second drug solution injector 7300 may contain glucagon.

The second chemical injection part 7300 may include a second storage part 7310 that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 7300 can include a module for injecting the second liquid medicine to the user, for example, a common needle module 7530, through which the second liquid medicine can be injected. The medicinal solution can be easily injected inside the user's skin.

As an alternative embodiment, the second medical fluid injector 7300 can include a second driver 7320 to deliver the second medical fluid in the second reservoir 7310 to the common needle module 7530 .

The second drug solution injection unit 7300 can use the blood sugar information from the blood sugar measurement unit 7100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measurement unit 7100 and the second drug injection unit 7300 may include a communication unit to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 7100 is below a set range via a control unit (not shown), the second chemical injection unit 7300 can inject the second chemical. For example, the second driving unit 7320 can be controlled to control the injection of the drug solution into the needle module.

Although not shown, the second drug injection part 7300 may include all or part of the same configuration as the driving part, storage part, and needle module included in the first drug injection part 7200 .

This embodiment includes a common needle module 7530 for injection of the first medical fluid and injection of the second medical fluid.

The common needle module 7530 is connected to a first reservoir 7210 storing a first drug solution and a second reservoir 7310 storing a second drug solution, thereby selectively supplying the first drug solution and the second drug solution. can be supplied. For example, the valve VL may supply the first chemical through the first reservoir 7210 or selectively supply the second chemical through the second reservoir 7310 .

Accordingly, it is possible to selectively and easily inject a desired liquid out of the first liquid and the second liquid into the injection target through the common needle module 7530 .

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

Also, the first chemical injection part or the second chemical injection part may include a storage part for storing the chemical solution and a driving part for driving the movement of the chemical solution. As a result, the operation of the drug-solution control injection device can be maintained smoothly.

Meanwhile, a common needle module configured to inject a drug solution into an injection target is included, and the common needle module is connected to a first reservoir storing a first drug solution and a second reservoir storing a second drug solution. be able to. Also, it is possible to selectively inject either one of the first chemical solution and the second chemical solution into the injection target through the common needle module as needed by controlling the valve or the like.

For example, when it is necessary to lower the blood glucose level, the valve is controlled to close the connection with the second reservoir, the first drug solution is supplied, the common needle module injects the first drug solution into the injection target, and the blood sugar level is lowered. When there is a need to increase, the valve is controlled to close the connection with the first reservoir, the second liquid is supplied, and the common needle module can inject the second liquid into the injection target.

As a result, the common needle module is commonly applied to the first chemical injection part and the second chemical injection part to reduce the space for arranging the needle modules, thereby increasing the degree of freedom in designing the space of the entire housing. Energy for control of the module can be reduced.

This makes it possible to enhance the convenience of handling and management of the liquid medicine control injection device including the blood glucose measuring section, the first liquid injection section, and the second liquid injection section.

As a result, the user's convenience can be enhanced through the liquid medicine control injection device of the present embodiment, and the injection of the first liquid medicine and the second liquid medicine can be precisely controlled, thereby precisely controlling the blood sugar of the user. can be done.

FIG. 16 is a schematic diagram for explaining a chemical liquid control injection device according to still another embodiment of the present invention.

Referring to FIG. 16 , the drug injection device 8500 of this embodiment may include a blood glucose measurement part 8100 , a first drug injection part 8200 , a second drug injection part 8300 and a housing 8510 .

The housing 8510 can have a unitary form, eg, a box shape.

As an alternative embodiment, the housing 8510 can have a form that includes a separate base and cover.

A part or all of the blood glucose measuring part 8100 , the first drug injection part 8200 and the second drug injection part 8300 may be covered with the housing 8510 .

For example, a cover (not shown) of the housing 8510 may cover one area or the entire area of the blood glucose measuring part 8100, the first drug injection part 8200, and the second drug injection part 8300. FIG.

The blood glucose measurement unit 8100 can be configured to measure the user's blood glucose at least sequentially multiple times.

As an alternative embodiment, the blood glucose measurement unit 8100 can continuously measure the user's blood glucose at periodic or irregular intervals for at least a set period of time, e.g. monitoring).

The first drug injection part 8200 may include a first storage part 8210 , a common driving part 8520 and a first needle module 8230 .

The first liquid medicine injection unit 8200 may be configured to reflect the blood glucose information measured by the blood glucose measurement unit 8100 and inject the first liquid medicine including components for controlling the decrease of blood glucose of the user to the user.

For example, the first liquid medicine injected to the user through the first liquid medicine injector 8200 may contain insulin.

As an alternative embodiment, the first chemical injector 8200 may include a first reservoir 8210 that stores the first chemical.

Since the first storage unit 8210 can selectively apply any one of the storage units described in the above embodiments, a detailed description thereof will be omitted.

In addition, as an alternative embodiment, the first medical fluid injector 8200 may include a module, eg, a first needle module 8230, for injecting the first medical fluid to the user.

The first needle module 8230 can include at least one needle portion ND. The needle part ND has a hollow shape, and the first drug solution of the first storage part 8210 can be injected into the injection target through the internal space.

Since the first needle module 8230 can selectively apply any one of the needle modules described in the above embodiments, a detailed description thereof will be omitted.

As an alternative embodiment, the first drug solution injector 8200 may include a common driver 8520 that transfers the first drug solution in the reservoir to the needle module.

The common driver 8520 may be connected to a power supply (not shown).

The common driving unit 8520 may selectively include any one of the driving units described in the above embodiments, and may include, for example, a pump unit.

The first drug solution injection unit 8200 can use the blood sugar information from the blood sugar measurement unit 8100 to inject the first drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 8100 exceeds a set range through a control unit (not shown), the first chemical injection unit 8200 can inject the first chemical, For example, the common driver 8520 can be controlled through a controller (not shown) to control the injection of the drug solution by the first needle module 8230 .

Such a control unit (not shown) may be included in the blood glucose measurement unit 8100 and may be included in the first drug injection unit 8200 or the second drug injection unit 8300 .

Also, a control unit (not shown) can be arranged as a separate member.

As an alternative embodiment, the control unit notifies the user or the like of the value measured by the blood glucose measurement unit 8100, and the user operates the control unit to control the injection of the first chemical injection unit 8200 or the second chemical injection unit 8300. You can also

The second drug injection part 8300 may include a second storage part 8310 , a common driving part 8520 and a second needle module 8330 .

The blood sugar information measured by the blood sugar measuring unit 8100 may be reflected to inject a second liquid medicine containing a component for controlling an increase in blood sugar of the user to the user.

For example, the second drug solution injected to the user through the second drug solution injector 8300 may contain glucagon.

The second chemical injection part 8300 may include a second storage part 8310 that stores the second chemical.

In addition, as an alternative embodiment, the second liquid medicine injector 8300 may include a module for injecting the second liquid medicine to the user, for example, a second needle module 8330, through which the second liquid medicine is injected. The two drug solutions can be easily injected inside the user's skin.

As an alternative embodiment, the second drug solution injection part 8300 may include a common driving part 8520 that transfers the second drug solution of the second storage part 8310 to the second needle module 8330 .

The second drug solution injection unit 8300 can use the blood sugar information from the blood sugar measurement unit 8100 to inject the second drug solution once, multiple times, or continuously as needed.

As an alternative embodiment, the blood glucose measuring unit 8100 and the second drug injection unit 8300 may include a communication unit to transmit information by wire or wirelessly.

As an alternative embodiment, when the blood glucose level measured by the blood glucose measuring unit 8100 is below a set range via a control unit (not shown), the second chemical injection unit 8300 can inject the second chemical. For example, the common drive 8520 can be controlled to control the injection of the drug solution into the needle module.

Although not shown, the second drug injection part 8300 may include all or part of the same configuration as the driving part, storage part, and needle module included in the first drug injection part 8200 .

In this embodiment, the driving force is transmitted to supply the first drug solution in the first reservoir 8210 to the first needle module 8230 and the second drug solution in the second reservoir 8310 to the second needle module 8330. includes a common drive portion 8520 that transmits drive power to the .

The common driving part 8520 is connected to a first storage part 8210 storing a first chemical and a second storage part 8310 storing a second chemical, thereby selectively supplying the first chemical to the first needle. The module 8230 can be supplied, or the second drug solution can be controlled to be supplied to the second needle module 8330 .

Accordingly, through the control of the common drive unit 8520, the desired chemical liquid out of the first chemical liquid and the second chemical liquid can be selectively and easily injected into the injection target.

The drug controlled infusion device of this embodiment is capable of measuring the user's blood glucose at least multiple times via the blood glucose measuring portion, or as an alternative embodiment, periodically or irregularly performing continuous blood glucose measurements. can be done. As a specific example, real-time blood glucose measurements can be performed.

Using the user's blood glucose information measured by the blood glucose measuring unit, the first chemical injection unit and the second chemical injection unit of the chemical control injection device can selectively inject the first chemical solution or the second chemical solution. can.

Accordingly, a user, for example, a user who cannot easily adjust blood sugar, can easily implement precise blood sugar control through the drug solution control injection device.

In addition, the first chemical injection part or the second chemical injection part includes a storage part for storing the chemical solution, a needle module configured to inject the chemical solution into the injection target, and a driving part for driving the movement of the chemical solution. can contain. With such a configuration, smooth injection of the first chemical solution or the second chemical solution can be easily implemented. In addition, the energy for driving the driving section can be easily supplied to the driving section through the power supply section, so that the operation of the liquid injection device can be smoothly maintained.

Meanwhile, a common driving part may be included which is connected to the first storage part and the second storage part to selectively provide the driving force. In addition, the common drive unit is controlled to selectively transmit the first chemical solution in the first reservoir to the first needle module or to selectively transmit the second chemical solution in the second reservoir to the second needle module as required. Thus, either one of the first chemical solution and the second chemical solution can be injected into the injection target.

For example, when the blood sugar level needs to be lowered, the driving force is transmitted to the first storage unit without transmitting the driving force to the second storage unit through the control of the drive control unit, and the first drug solution in the first storage unit is When the first medicinal solution is supplied to the first needle module and needs to be injected into the injection target to raise the blood sugar level, the driving force is not transmitted to the first reservoir through the control of the drive control unit, and the second reservoir is and the second liquid medicine in the second reservoir is supplied to the second needle module to inject the second liquid medicine into the injection target.

Accordingly, the common driving part is commonly applied to the first chemical injection part and the second chemical injection part, thereby reducing the space for arranging the driving part, thereby increasing the degree of freedom in designing the space of the entire housing. Energy for control of parts can be reduced.

Also, the blood glucose measuring part, the first drug injection part, and the second drug injection part may be included in the housing, and for example, at least one region thereof may be covered by a cover of the housing. Also, as a specific example, it can have an integrated form. This makes it possible to enhance the convenience of handling and management of the liquid medicine control injection device including the blood glucose measuring section, the first liquid injection section, and the second liquid injection section.

As a result, the user's convenience can be enhanced through the liquid medicine control injection device of the present embodiment, and the injection of the first liquid medicine and the second liquid medicine can be precisely controlled, thereby precisely controlling the blood sugar of the user. can be done.

FIG. 17 is a diagram illustrating an alternative embodiment of a driver included in a drug control injection device according to yet another embodiment of the present invention;

For example, FIG. 17 can be applied to any of the first driving section of the first liquid injection section, the second driving section of the second liquid injection section, or the commonly applied common driving section included in the liquid controlled injection device. 1, a pump portion 120 is shown.

Specifically, the pump unit 120 and the pump unit described in the embodiments described below may be at least one of the first driving unit, the second driving unit and the common driving unit of the above embodiments. It can be applied, partially applied, or partially modified as needed.

Referring to FIG. 17, the housing 110 of the pump unit 120 includes a shaft hole 112H provided on one side, through which a shaft 130 having a predetermined length can extend outside the housing 110. . In one embodiment, the shaft hole 112H may be formed in a protrusion 112 extending to one side with respect to the body 111 of the housing 110, and the diameter of the protrusion 112 may be smaller than the diameter of the body 111. can be done.

A first portion 131 of the shaft 130 is disposed inside the housing 110 and a second portion 132 can extend outside the housing 110 through the shaft hole 112H. The shaft 130 can reciprocate along the vertical direction (z direction) in FIG. When the shaft 130 reciprocates, the first portion 131 may linearly reciprocate within the inner space of the housing 110 , for example, the inner space corresponding to the protrusion 112 . Since the diameter R1 of the first portion 131 of the shaft 130 is larger than the diameter R3 of the shaft hole 112H, the first portion 131 cannot be pulled out of the housing 110. FIG.

As an alternative embodiment, the second portion 132 of the shaft 130 can have a diameter R2 that is less than the diameter R3 of the shaft hole 112H. At this time, the second portion 132 may be coupled with the movement control portion 113 disposed outside the housing 110 to prevent the second portion 132 from slipping out of the shaft hole 112H.

A seal member 125 may be disposed on the side of the first portion 131 of the shaft 130 . The inner space of the housing 110, for example, the space defined by the inner surface of the housing 110 and the inner surface of the shaft 130, is a closed space, the inner space contains a fluid, and the seal 125 is provided between the housing 110 and the shaft 130. Leakage of fluid into the gap between the shaft 130 and the shaft 130 can be restricted. In FIG. 17, the fluid is omitted for convenience of explanation.

According to one embodiment, as shown in FIG. 17, a seal 125 in the form of an O-ring may cover the sides of the first portion 131, the seal 125 allowing fluid present inside the housing 110 to flow through the shaft. Leakage (leakage) to the outside of the housing 110 through the hole 112H can be prevented. Fluid leakage can be further effectively limited by forming the first distance D1 from the first portion 131 of the shaft 120 to the movement control portion 113 equal to or less than the inner length D2 of the protrusion 112. can be done.

The membrane 140 can be disposed in an interior space of the housing 110 , eg, an interior space corresponding to the main body 111 . The internal space includes a first space S1 and a second space S2 located on both sides of the membrane 140, respectively. In FIG. 17, the space distant from the shaft 130 with the membrane 140 as the reference is the first space S1, and the space adjacent to the shaft 130 with the membrane 140 as the reference is the second space S2.

Membrane 140 can have a porous structure that allows fluid and ion movement. Membrane 140 may be, for example, a frit-like membrane made by thermally calcining spherical silica. For example, the spherical silica used to form the membrane can have a diameter of about 20 nm to about 500 nm, specifically about 30 nm to about 300 nm, and more specifically about It can have a diameter of 40 nm to about 200 nm. If the diameter of the spherical silica satisfies the above range, the first fluid passing through the membrane 140 can generate enough pressure to move the shaft 130 .

Although membrane 140 has been described as including spherical silica, membrane 140 is not so limited. In another embodiment, the membrane 140 is not limited to any material, such as porous silica or porous alumina, as long as it can cause an electrokinetic phenomenon due to zeta potential. do not have.

The membrane 140 can have a thickness of about 20 μm to about 10 mm, specifically about 300 μm to about 5 mm, and more specifically about 1,000 μm to about 4 mm. can have a thickness of

A first electrode body 150 and a second electrode body 160 are disposed on both sides of the membrane 140, respectively. The first electrode body 150 can include a first porous plate 151 and first electrode strips 152 disposed on the first side of the membrane 140 . The second electrode body 160 can include a second porous plate 161 and a second electrode strip 162 positioned on the second side of the membrane 140 .

The first and second porous plates 151, 161 can be arranged to contact both main surfaces of the membrane 140, respectively. The first and second porous plates 151, 161 can effectively move fluids and ions through the porous structure. The first and second porous plates 151 and 161 may have a structure in which an electrochemical reactant is formed on a porous base layer. The electrochemical reactant can be formed by electrodeposition or coating onto the porous base layer by methods such as electroless plating, vacuum deposition, coating, sol-gel processes, and the like.

The porous base layer may be an insulator. For example, the porous base layer can include one or more selected from non-conductive ceramics, non-conductive polymeric resins, non-conductive glasses, and combinations thereof.

Non-conductive ceramics can include, for example, one or more selected from the group consisting of rock wool, gypsum, ceramics, cement and combinations thereof, specifically rock wool, gypsum and combinations thereof. but are not limited to, one or more selected from the group consisting of

The non-conductive polymeric resin is selected from the group consisting of synthetic fibers, such as those selected from the group consisting of, for example, polypropylene, polyethylene terephthalate, polyacrylonitrile, and combinations thereof; wool, cotton, and combinations thereof. sponges; porous materials derived from living organisms, such as the bones of living organisms; and combinations thereof. not something.

The non-conductive glass can include, but is not limited to, one or more selected from the group consisting of glass wool, glass frit, porous glass, and combinations thereof.

The porous base layer can have a pore size from about 0.1 μm to about 500 μm, specifically from about 5 μm to about 300 μm, and more specifically from about 10 μm to about 10 μm. It can have a pore size of about 200 μm. When the pore size of the porous support satisfies the above range, the fluid and ions can be effectively transferred, and the stability, life characteristics and efficiency of the pump unit 120 can be improved.

The electrochemical reactant is capable of forming a pair of reactions in which the oxidation electrode and the reduction electrode exchange cations, for example, hydrogen ions, during the electrode reaction of the first and second electrode bodies 150 and 160, and at the same time reversible electricity. It can contain substances capable of forming a chemical reaction. Electrochemical reactants include, for example, silver/silver oxide, silver/silver chloride, MnO(OH), polyaniline, polypyrrole, polythiophene, polythionine, quinone-based polymer) and combinations thereof.

The first and second strips 152, 162 can be arranged on the edges of the first and second porous plates 151, 161 and connected with the first and second terminals 153, 163 outside the housing 110. be able to. The first and second strips 152, 162 may include conductive materials such as silver and copper.

The fluid provided in the inner space of the housing 110 may include a first fluid and a second fluid having different phases. The first fluid may comprise liquid such as water and the second fluid may comprise gas such as air. The first fluid present in the interior space does not entirely fill the interior space. That is, the volume of the internal space is greater than the volume of the first fluid present in the internal space. The second fluid exists in the portion of the internal space where water does not exist.

Sealing materials 117 are arranged on both sides of the structure of the membrane 140 , the first electrode body 150 and the second electrode body 160 . The sealant 117 may be annular with an area corresponding to the edge of the structure previously described. The aforementioned fluid, for example, the first fluid, moves along the thickness direction of the membrane 140 from the first space S1 to the second space S2 or vice versa so as to pass through the membrane 140, when , the sealing material 117 closes the gap between the inner surface of the housing 110 and the structure described above, and can prevent liquid from moving through the gap.

Fluid can enter the interior space through inlet 118 . In one embodiment, after the first fluid is completely filled into the internal space through both inlets 118 , a part of the first fluid is extracted to the outside through one of the inlets 118 and then injected. By closing inlet 118 , a first fluid and a second fluid can reside in the interior space of housing 110 .

Although not shown, the first electrode body 150 and the second electrode body 160 may be connected to a power supply through terminals, respectively, and alternately change the polarity of the voltage of the power supply to move liquid such as water. can change direction.

Also, the movement of the shaft 130 of the pump unit 120 can be controlled through such control. Such movement of the shaft 130 facilitates precise control of the movement of the first chemical solution or the second chemical solution of the above-described embodiments.

FIG. 18 is a diagram illustrating an alternative embodiment of a driver included in a drug control injection device according to yet another embodiment of the present invention;

For example, in FIG. 18, any one of the first drive unit of the first drug injection unit, the second drive unit of the second drug injection unit, or the commonly applied common drive unit included in the drug control injection device is shown. An applicable pump portion 229 is shown.

The pump unit 229 of FIG. 18 may be a pump that utilizes electroosmotic pressure.

Referring to FIG. 18, the housing 210 of the pump part 229 includes a shaft hole 212H provided on one side, through which the shaft 220 having a predetermined length can extend outside the housing 210. .

In one embodiment, the shaft hole 212H may be formed in a protrusion 212 extending to one side with respect to the body 211 of the housing 210, and the diameter of the protrusion 212 may be smaller than the diameter of the body 211. can be done.

A first portion 221 of shaft 220 is disposed inside housing 210 and a second portion 222 extends outside housing 110 through shaft hole 112H as described above. The shaft 220 can reciprocate along the vertical direction (Z direction).

The second portion 222 of the shaft 220 may have a diameter R2 smaller than the diameter R3 of the shaft hole 212H, and as an alternative embodiment, the second portion 222 is coupled with the movement control portion 213 arranged outside the housing 210. can do.

A sealant 225 may be disposed on the side of the first portion 221 of the shaft 220 .

Membrane 214 can be disposed in an interior space of housing 110 , for example, an interior space corresponding to main body 211 . The internal space includes a first space S1 and a second space S2 located on both sides of the membrane 214, respectively.

In FIG. 18, the space far from the shaft 220 with the membrane 214 as the reference is the first space S1, and the space adjacent to the shaft 220 with the membrane 214 as the reference is the second space S2.

Membrane 214 can have a porous structure that allows fluid and ion movement. The membrane 214 may be, for example, a frit-like membrane made by thermally sintering spherical silica. For example, the spherical silica used to form the membrane can have a diameter of about 20 nm to about 500 nm, specifically about 30 nm to about 300 nm, and more specifically about It can have a diameter of 40 nm to about 200 nm.

If the diameter of the spherical silica satisfies the above range, the first fluid passing through the membrane 214 can generate enough pressure to move the shaft 220 .

Although the membrane 214 contains spherical silica in the above embodiment, the membrane 214 is not limited to this.

In another embodiment, the membrane 214 is not limited to any material, such as porous silica or porous alumina, as long as it can cause an electrokinetic phenomenon due to zeta potential. do not have.

The membrane 214 can have a thickness of about 20 μm to about 10 mm, specifically about 300 μm to about 5 mm, more specifically about 1,000 μm to about 4 mm. can have a thickness of

A first electrode body 250 and a second electrode body 260 are disposed on both sides of the membrane 214, respectively. The first electrode body 250 can include a first porous plate 251 and first electrode strips 252 disposed on the first side of the membrane 214 . The second electrode body 260 can include a second porous plate 261 and a second electrode strip 262 positioned on the second side of the membrane 214 .

The first and second porous plates 251 , 261 can be arranged to contact both main surfaces of the membrane 214 , respectively. The first and second porous plates 251, 261 can effectively move fluids and ions through the porous structure.

The first and second porous plates 251 and 261 may have a structure in which an electrochemical reactant is formed on a porous base layer. The electrochemical reactant can be formed by electrodeposition or coating onto the porous base layer by methods such as electroless plating, vacuum deposition, coating, sol-gel processes, and the like.

The porous base layer may be an insulator. For example, the porous base layer can selectively apply one or more of the materials described in the embodiment of FIG. 6 above.

When the pore size of the porous support satisfies the aforementioned ranges, it can effectively move fluids and ions, and improve the stability, lifetime characteristics, and efficiency of the pump part 229 .

The electrochemical reactant is capable of forming a pair of reactions in which the oxidation electrode and the reduction electrode exchange cations, for example, hydrogen ions, during the electrode reaction of the first and second electrode bodies 250 and 260, and at the same time reversible electricity. It can contain substances capable of forming a chemical reaction.

Electrochemical reactants include, for example, silver/silver oxide, silver/silver chloride, MnO(OH), polyaniline, polypyrrole, polythiophene, polythionine, quinone-based polymer) and combinations thereof.

The first and second strips 252, 262 can be arranged on the edges of the first and second porous plates 251, 261 and connected with the first and second terminals 253, 263 outside the housing 210. be able to. The first and second strips 252, 262 may include conductive materials such as silver and copper.

The fluid provided in the inner space of the housing 210 may include a first fluid and a second fluid having different phases. The first fluid may comprise liquid such as water and the second fluid may comprise gas such as air.

The first fluid present in the interior space does not entirely fill the interior space. That is, the volume of the internal space is greater than the volume of the first fluid present in the internal space. The second fluid exists in the portion of the internal space where water does not exist.

A sealing material 217 is arranged on both sides of the structure of the membrane 214 , the first electrode body 250 and the second electrode body 260 . The sealant 217 may be annular with an area corresponding to the edge of the structure previously described.

The aforementioned fluid, for example the first fluid, moves along the thickness direction of the membrane 214 from the first space S1 to the second space S2 or vice versa so as to pass through the membrane 214, when , the sealing material 217 closes the gap between the inner surface of the housing 210 and the structure described above, and can prevent liquid from moving through the gap.

Fluid behavior and resulting shaft movement will now be described.

The first electrode body 250 and the second electrode body 260 are electrically connected to the power supply through the first and second terminals 253 and 263, respectively, and alternately change the polarity of the voltage supplied by the power supply. By supplying, the moving direction of a liquid such as water can be changed.

In one embodiment, using silver/silver oxide as the electrochemical reactant and the first fluid being a solution containing water, the first electrode body 250 is the oxidation electrode and the second electrode body 260 is In the case of a reduction electrode, the cations (eg, hydrogen ions) generated by the oxidation reaction at the first electrode body 250 move through the membrane 214 toward the second electrode body 260 due to the voltage difference. At times, a certain pressure may be generated while water (H ₂ O) moves with the cations.

Through such control, the movement of the shaft 220 of the pump portion 229 can be controlled.

FIG. 19 is a perspective view showing an alternative embodiment of a drive unit included in a drug liquid controlled injection device according to still another embodiment of the present invention, and FIG. 20 is a perspective view taken along line XX-XX of FIG. Figure 3 is a cutaway cross-sectional view;

For example, FIGS. 19 and 20 show either the first driving section of the first chemical injection section, the second driving section of the second chemical injection section, or the commonly applied common driving section included in the chemical liquid control injection device. One applicable pump section 320 is shown.

The pump portion 320 of this embodiment can include a connector 321 and a check valve assembly 323 and can also include a drive member 325 .

A check valve assembly 323 may be coupled to one side of the connector 321 and a driving member 325 may be coupled to the other side. The connector 321 may be provided with a partition 321 a that separates the check valve assembly 323 and the driving member 325 . The partition 321a may be provided with an inlet 321b and an outlet 321c.

The inflow port 321b and the outflow port 321c are spaced apart from each other through the partition wall 321a.

Check valve assembly 323 may include valve housing 357 , inlet check valve 359 , outlet check valve 361 , first fixture 363 , and second fixture 365 .

The valve housing 357 may be provided with an inflow extension line 357a and an exhaust extension line 357b. A valve housing 357 can be coupled to one side of the connector 321 . The inflow extension pipeline 357a is connected to the inflow port 321b, and the discharge extension pipeline 357b is connected to the outflow port 321c.

An inflow check valve 359 is disposed in the inflow extension line 357a and can control the direction of passage of the fluid. A discharge check valve 361 is disposed in the discharge extension line 357b and can control the direction of fluid passage.

The inflow check valve 359 and the discharge check valve 361 may be flexible and low opening pressure Duckbill valves. The inflow check valve 359 and the discharge check valve 361 can increase the efficiency of fluid transmission with respect to power consumption, can operate for a long period of time, and can increase marketability.

The first fixture 363 may serve to fix the inflow check valve 359 by being fitted into the inflow extension pipe 357a. The second fixture 365 may serve to fix the discharge check valve 361 by being fitted into the discharge extension pipe 357b.

The first fixture 363 and the second fixture 365 preferably comprise conduits.

In the embodiment of the present invention, an example in which the inflow check valve 359 and the discharge check valve 361 are coupled to the valve housing 357 has been described. An inlet check valve 359 and an outlet check valve 361 may be coupled to the inlet 321b and outlet 321c, respectively. Such another example can be made with a simpler structure by configuring the valve housing 357 integrally with the connector 321 . Such other examples of embodiments of the present invention can be made compact with fewer parts to further reduce manufacturing costs.

A driving member 325 is coupled to one side of the connector 321 . Actuating member 325 is preferably located on the opposite side to which check valve assembly 323 is coupled. The drive member 325 is preferably located isolated from the fluid passing through the check valve assembly 323 . Drive member 325 may provide pressure to fluid passing through check valve assembly 323 .

The driving member 325 includes a first diaphragm 367, a first pump housing 329, a first power supply line 371, a first electrode 373, a membrane 327, a second electrode 377, a second power supply line 379, a second pump housing 381, and A second diaphragm 383 may be included.

A first diaphragm 367 is coupled to one side of the connector 321 . A space may be provided between the first diaphragm 367 and the connector 321 . That is, the first diaphragm 367 is coupled to the connector 321 while maintaining a certain space between the connector 321 and the connector 321 . Therefore, the fluid on the side of the check valve assembly 323 is kept isolated by the first diaphragm 367 without moving to the side of the driving member 325 .

The surface of the first diaphragm 367 can be repeatedly moved in the axial direction by pressure generated from the driving member 325 . In some cases, the first diaphragm 367 may be provided with wrinkles whose surface can move smoothly in the axial direction.

One side of the first pump housing 329 is coupled with the above-described first diaphragm 367 . A space 329a may be provided through the first pump housing 329 along the axial direction. Therefore, the first pump housing 329 can close one side of the space 329 a by the first diaphragm 367 .

A first electrode 373 is coupled to the other side of the first pump housing 329 to close the space 329 a formed by the first pump housing 329 . Further, the first pump housing 329 may accommodate a working fluid such as water in a space 329a provided therein.

The first pump housing 329 may be provided with a fluid injection hole 329b on its outer periphery. Such holes 329 b can be sealed after the working fluid is injected into the first pump housing 329 . Accordingly, the working fluid in the drive member 325 can be isolated from the chemical liquid on the check valve assembly 323 side.

The first power supply line 371 may supply power to the first electrode 373 . The first power supply line 371 may be arranged along the frame of the first pump housing 329 and fixed in contact with the first electrode 373 . The first power supply line 371 is preferably arranged between the first pump housing 329 and the first electrode 373 . However, as another example of an embodiment of the present invention, the first power supply line 371 can be placed between the first electrode 373 and the membrane 327 if only the first electrode 373 can be powered. is also possible.

The first electrode 373 is plate-shaped and can close the space 329 a of the first pump housing 329 . That is, the first pump housing 329 can form a space 329 a with the first diaphragm 367 and the first electrode 373 . A working fluid such as water is accommodated in the space 329 a of the first pump housing 329 .

The membrane 327 may be made of a porous material through which the working fluid and ions are transferred. Membrane 327 is preferably made of a non-conductor such as ceramic. When the membrane 327 is made of a non-conductor, the electroosmotic pump of the present invention is operated for a long period of time, and the electrochemical reactants used for the first electrode 373 and the second electrode 377 are consumed or desorbed, and the porous membrane is formed. Even if 327 is exposed, side reactions will not occur. Therefore, unnecessary power consumption due to side reactions can be prevented. Therefore, the present invention has safe driving characteristics and can improve durability.

The membrane 327 can be used by processing a flexible material such as polymer resin, rubber, urethane, or plastic film that does not exhibit conductivity into a thin film.

A second electrode 377 is disposed on the other side of the membrane 327 . That is, membrane 327 is preferably arranged between first electrode 373 and second electrode 377 . The second power supply line 379 can supply external power to the second electrode 377 . A second power supply line 379 may be coupled to the frame of the second pump housing 381 . However, the second power supply line 379 can be arranged in any structure as long as it can simply supply power to the second electrode 377 .

The second pump housing 381 has the same or similar shape and pattern as the first pump housing 329 . The second pump housing 381 may be axially provided with another space 381a. Like the first pump housing 329, the second pump housing 381 may be provided with a hole 381b penetrating the internal space 381a. The hole 381b of the second pump housing 381 may be sealed with a sealant after the working fluid is injected, or may be embedded by fusion bonding or the like.

The second diaphragm 383 may be coupled to one side of the second pump housing 381 to close the space 381 a provided in the second pump housing 381 .

That is, the second pump housing 381 can close the space 381 a with the plate-shaped second electrode 377 and the second diaphragm 383 .

The second diaphragm 383 may have creases 383a formed on its surface. The wrinkle portion 383a formed in the second diaphragm 383 may be formed as unevenness protruding in the axial direction when viewed on the basis of a cross section. The wrinkled portion 383a of the second diaphragm 383 may serve to sufficiently move the surface of the second diaphragm 383 in the axial direction to increase pumping performance.

In the embodiment of the present invention, the second diaphragm 383 has the wrinkled portion 383a. However, the first diaphragm 367 may have the wrinkled portion as well. In addition, the wrinkles that can be formed in the first diaphragm 367 or the second diaphragm 383 maximize deformation of the first diaphragm 367 and the second diaphragm 383 even with low energy, thereby reducing energy consumption. That is, there is an advantage that the driving member 325 can be driven for a long time even with a low external power supply.

The first pump housing 329, the first power supply line 371, the first electrode 373, the membrane 327, the second electrode 377, the second power supply line 379, and the second pump housing 381 are hermetically sealed from the outside by the sealant S. can be maintained. That is, the first power supply line 371 , the first electrode 373 , the membrane 327 , the second electrode 377 , and the second power supply line 379 are configured to be smaller than the first pump housing 329 and the second pump housing 381 . In the assembled state, the peripheral portion (the portion exposed to the outside and forming a groove or space based on the cross section) is sealed between the first pump housing 329 and the second pump housing 381. An agent S can be placed. Such a sealant S can form an airtight layer that maintains airtightness with the outside.

Figure 21 is a perspective view of yet another alternative embodiment of a drug control injection device according to yet another embodiment of the present invention;

Referring to FIG. 21, the drug control injection device 9000 can include a cover portion 9250 and a base plate 9260. As shown in FIG.

At least one or a plurality of regions of the blood glucose measurement unit, the first drug injection unit, and the second drug injection unit of the above-described embodiments may be disposed on the base plate 9260 or supported by the base plate 9260, and may be covered by the cover. It can be covered by part 9250 . As a result, the drug solution control injection device 9200 can be used as an integrated module, and the user's convenience can be improved. Of course, the first chemical injection section and the second chemical injection section can be housed in separate housings.

Also, as an alternative embodiment, the drug control injection device 9000 can be connected to an external terminal MDV. The user can receive information from the drug control infusion device 9000 via the terminal MDV, and as another example, start or end the operation of the drug control infusion device 9000 via the terminal MDV. can be done.

In addition, it is possible to grasp the operating state and performance status of the drug solution control injection device 9000 periodically or in real time.

For this purpose, the terminal MDV can be connected to the drug control injection device 9000 via a wired or wireless communication module, and the drug control injection device 9000 can include such a communication module.

As a result, the convenience of injecting the liquid medicine to the injection target can be improved, and more specifically, the precise control of the first liquid medicine and the second liquid medicine, which are different liquid medicines when the blood sugar decreases and increases, can be easily realized. .

In addition, a user such as an injection target related to drug solution injection, a guardian of a drug solution injection target, a medical person, or the like can easily check drug solution injection information for the drug solution injection target and changes in blood sugar after drug solution injection. The infusion subject's glycemic control can be precisely controlled.

Thus, although the present invention has been described with reference to the embodiments shown in the figures, this is by way of example only and will allow those of ordinary skill in the art to make various modifications. It will be appreciated that other variations and equivalents are possible. Therefore, the true technical scope of protection of the present invention should be determined by the technical ideas of the appended claims.

The use of the term "above" and similar referential terms in the description of embodiments (especially in the claims) may cover both singular and plural forms. In addition, when a range is described in the embodiment, it includes an invention to which an individual value belonging to the above range is applied (unless there is a description to the contrary), and each individual constituting the above range is included in the detailed description. is the same as that for which the value of Finally, where steps constituting a method according to an embodiment are explicitly stated in order or not stated to the contrary, the steps may be performed in any suitable order. The order in which the steps are described does not necessarily limit the embodiments. The use of any example or exemplary terminology (eg, etc.) in the embodiments is merely to describe the embodiments in detail, unless limited by the claims. The terms are not intended to limit the scope of the embodiments. Moreover, those of ordinary skill will appreciate that various modifications, combinations and changes may be made depending on design considerations and factors within the scope of the appended claims or equivalents thereof.

The specific implementation described in the embodiment is an embodiment and does not limit the scope of the embodiments in any way. For the sake of brevity, descriptions of conventional electronic components, control systems, software, and other functional aspects of the system may be omitted. Furthermore, line connections or connecting members between components shown in the drawings are illustrative of functional connections and/or physical or circuit connections and may be substituted or added in an actual device. can be shown as various functional, physical, or circuit connections. Furthermore, unless there is a specific reference such as "essential", "important", etc., it may not be a necessary component to apply the present invention.

Claims (7)

a blood glucose measuring portion configured to measure the blood glucose of an infusion subject at least sequentially multiple times;
a first drug solution injection unit configured to inject a first drug solution containing a component that controls a decrease in blood sugar of the injection target into the injection target;
a second drug solution injection unit configured to inject a second drug solution into an injection target, the second drug solution including a component that controls an increase in blood sugar of the injection target and a component different from the first drug solution. . 2. The chemical liquid control injection device according to claim 1, wherein the first chemical liquid injection section and the second chemical liquid injection section are formed to selectively inject the first chemical liquid or the second chemical liquid into an injection target. 2. The liquid medicine control according to claim 1, further comprising a controller configured to control driving of the first liquid medicine injector and the second liquid medicine injector according to the blood sugar information measured by the blood glucose measuring part. injection device. The first chemical injection section or the second chemical injection section includes a housing,
2. The drug control injection device according to claim 1, wherein the blood glucose measurement unit comprises one disposed within a housing of the first drug feeder or the second drug feeder. 2. The drug control injection device according to claim 1, comprising a housing formed to contain at least one of the blood glucose measuring unit, the first drug injection unit and the second drug injection unit. [Claim 2] The chemical control injection device according to claim 1, which is formed to communicate with a terminal separately provided from the chemical control injection device to transmit one or more information. 2. The drug control injection device according to claim 1, wherein the drug control injection device is attached to the outside of the user's body and includes a wearable function.

Images